Adicet Bio to Present at Upcoming Investor Conferences

Adicet Bio (NASDAQ: ACET), a clinical-stage biotechnology firm focused on allogeneic gamma delta CAR T cell therapies for cancer, announces management's participation in three investor conferences in August 2022.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.

Details of the events are as follows:

BTIG Biotech Conference, August 8-9, 2022

• Chen Schor, President & CEO, will participate in a fireside chat at the conference on Monday, August 8, 2022.

Wedbush Pacgrow Healthcare Conference, August 9-10, 2022

• Chen Schor, President & CEO, will participate in a virtual panel discussion titled, “A View to a Kill(er) Cell – Part 1” on Wednesday, August 10, 2022, at 1:10 P.M. ET.

Canaccord Genuity Annual Growth Conference, August 8-11, 2022, Boston, Massachusetts

• Chen Schor, President & CEO, will present a corporate overview on Thursday, August 11, 2022, at 11:00 A.M. ET.

The live audio webcast of the Canaccord Genuity presentation and Wedbush panel can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005661/en/

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.